NurExone Biologic Announces Corporate Updates including Israel Patent Grant and Private Placement Closing

TORONTO and HAIFA, Israel, Sept. 11, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a pioneering biopharmaceutical company developing exosome-based regenerative therapies, is pleased to provide the following corporate updates.

Israeli Patent Grant Expands Global Jurisdiction

The Israel Patent Office has granted the Company’s Patent, entitled “Production of Extracellular Vesicles from Stem Cells.” This grant aligns with NurExone’s recently announced U.S. Notice of Allowance for the same priority family of applications.

“While our clinical and commercial manufacturing of exosomes will be based in the U.S. through our Exo-Top Inc. subsidiary, expanding jurisdictional coverage further strengthens NurExone’s international intellectual property portfolio,” said Dr. Lior Shaltiel, CEO of NurExone.

Management Participation at U.S. Conferences

Dr. Ina Sarel, Head of CMC, Quality and Regulation, will present on NurExone’s exosome manufacturing platform at the 7th Annual Exosome-Based Therapeutic Development Summit in Boston, MA, a leading international meeting for exosome research and drug development. She will be co-hosting a fireside discussion entitled “Harmonizing the Exosome & Extra-Cellular Vesicle Regulatory Landscape Towards Better Definitions, Practices & Guidelines for Therapeutic Success.

Dr. Lior Shaltiel, CEO, will speak at the Bioprocess International Conference in Boston, MA, one of the largest global gatherings for biomanufacturing innovation. His presentation is entitled “From Antibodies to siRNA-Loaded Exosomes: AbbVie vs. NurExone in Advancing Spinal Cord Injury Treatments”.

These high-profile conferences provide opportunities for NurExone to showcase its proprietary ExoTherapy technology, expand U.S. presence, and engage potential partners and investors.

Private Placement

The Company is also pleased to announce that, subject to TSX Venture Exchange (“TSXV”) approval, it has closed a non-brokered private placement of 930,376 units (“Units”) at a price of C$0.68 per Unit for aggregate gross proceeds of C$632,655.68 (the “Offering”). The Company intends to use the proceeds of the Offering for working capital purposes.

“The completion of this financing provides incremental capital to support our preclinical pipeline and U.S. manufacturing initiatives,” said Eran Ovadya, CFO of NurExone. “It also positions us well as we prepare to accelerate our growth strategy.”

Terms of the Offering

Each Unit consisted of (i) one common share in the capital of the Company (each, a “Common Share”), and (ii) one-half of one Common Share purchase warrant (each whole warrant, a “Warrant”). Each Warrant entitles the holder thereof to purchase one Common Share at a price of C$0.88 per Common Share for a period of 36 months, subject to acceleration. If the daily volume weighted average trading price of the Common Shares on the TSXV for any period of 20 consecutive trading days equals or exceeds C$1.70, the Company may, upon providing written notice to the holders of the Warrants (the “Acceleration Notice”), accelerate the expiry date of the Warrants to the date that is 45 days following the date of the Acceleration Notice. If the Warrants are not exercised by the accelerated expiry date, the Warrants will expire and be of no further force or effect.

Closing of the Offering is subject to receipt of all necessary regulatory approvals, including the TSXV, and all securities issued under the Offering are subject to a statutory hold period of four months and one day from the closing of the Offering.

Related Party Transaction

Jay Richardson, a director of the Company, participated in the Offering and acquired 24,854 Units. The participation of Mr. Richardson in the Offering constituted a “related party transaction” and such term is defined in Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transaction (“MI 61-101”) and would have required the Company to receive minority shareholder approval for and obtain a formal valuation for the subject matter of the Offering in accordance with MI 61-101, prior to the completion of the Offering. However, in completing the Offering, the Company has relied on exemptions from the formal valuation and minority shareholder approval requirements of MI 61-101 contained in sections 5.5(a) and 5.7(1)(a) of MI 61-101 in respect of Mr. Richardson’s participation in the Offering as neither the fair market value (as determined under MI 61-101) of the subject matter of, nor the fair market value of the consideration for, the Offering, insofar as it involved insiders, exceeded 25% of the Company’s market capitalization (as determined under MI 61-101).

The Offering was approved by the members of the board of directors of the Company who are independent for the purposes of the Offering insofar as it involved Mr. Richardson. No special committee was established in connection with the Offering.

Further details will be included in a material change report to be filed by the Company. The Company did not file a material change report more than 21 days before the closing date of the Offering as Mr. Richardson’s subscription was not known until closing and the subscribers requested to close the Offering in an expeditious manner. In the Company's view, the shorter period was necessary to permit the Company to close the Offering in a timeframe consistent with usual market practice for transactions of this nature and was reasonable in the circumstances.

About NurExone

NurExone Biologic Inc. is a TSXV, OTCQB, and Frankfurt-listed biotech company focused on developing regenerative exosome-based therapies for central nervous system injuries. Its lead product, ExoPTEN, has demonstrated strong preclinical data supporting clinical potential in treating acute spinal cord and optic nerve injury, both multi-billion-dollar marketsⁱ . Regulatory milestones, including obtaining the Orphan Drug Designation, facilitates the roadmap towards clinical trials in the U.S. and Europe. Commercially, the Company is expected to offer solutions to companies interested in quality exosomes and minimally invasive targeted delivery systems for other indications. NurExone has established Exo-Top Inc., a U.S. subsidiary, to anchor its North American activity and growth strategy.

For additional information and a brief interview, please watch Who is NurExone?, visit www.nurexone.com or follow NurExone on LinkedIn, Twitter, Facebook, or YouTube.

For more information, please contact:

Dr. Lior Shaltiel
Chief Executive Officer and Director
Phone: +972-52-4803034
Email: info@nurexone.com

Dr. Eva Reuter
Investor Relations – Germany
Phone: +49-69-1532-5857
Email: e.reuter@dr-reuter.eu

Allele Capital Partners
Investor Relations – U.S.
Phone: +1 978-857-5075
Email: aeriksen@allelecapital.com

FORWARD-LOOKING STATEMENTS

This press release contains certain “forward-looking statements” that reflect the Company’s current expectations and projections about its future results. Wherever possible, words such as “may”, “will”, “should”, “could”, “expect”, “plan”, “intend”, “anticipate”, “believe”, “estimate”, “predict” or “potential” or the negative or other variations of these words, or similar words or phrases, have been used to identify these forward-looking statements. Forward-looking statements in this press release include, but are not limited to, statements relating to: clinical and commercial manufacturing of the Company’s exosomes will be based in the U.S.; Dr. Sarel and Dr. Shaltiel presenting in the upcoming events as outlined herein; Dr. Sarel co-hosting a fireside discussion as outlined herein; the Company expanding its U.S. presence and engaging potential partners and investors; the Company receiving all regulatory approvals, including TSXV approval, for the Offering; the use of proceeds from the Offering; long-term protection of the Company’s intellectual property and manufacturing process; and the NurExone platform technology offering novel solutions to drug companies interested in minimally invasive targeted drug delivery for other indications.

These statements reflect management’s current beliefs and are based on information currently available to management as at the date hereof. In developing the forward-looking statements in this press release, we have applied several material assumptions, including: the Company’s clinical and commercial manufacturing of exosomes will be based in the U.S.; Dr. Sarel and Dr. Shaltiel will present in the upcoming events as outlined herein; Dr. Sarel will co-host a fireside discussion as outlined herein; the Company will expand its U.S. presence and engage potential partners and investors; the Company will receive all regulatory approvals, including TSXV approval, for the Offering; the Company will use the proceeds from the Offering as outlined herein; the Company will have long-term protection of its intellectual property and manufacturing process; and the NurExone platform technology will offer novel solutions to drug companies interested in minimally invasive targeted drug delivery for other indications.

Forward-looking statements involve significant risk, uncertainties and assumptions. Many factors could cause actual results, performance or achievements to differ materially from the results discussed or implied in the forward-looking statements. These risks and uncertainties include, but are not limited to risks related to: the Company’s clinical and commercial manufacturing of exosomes will not be based in the U.S.; Dr. Sarel and/or Dr. Shaltiel will not present in the upcoming events as outlined herein; Dr. Sarel will not co-host a fireside discussion as outlined herein; the Company will not expand its U.S. presence and/or engage potential partners and/or investors; the Company will not receive all required regulatory approvals, including TSXV approval; the Company will not use the proceeds from the Offering as outlined herein; government regulation; the Company’s early stage of development; lack of revenues to date; the inherent uncertainty of preclinical drug development, including the risk that product candidates may not advance to clinical trials or receive regulatory approval; the possibility that results from preclinical studies and early-stage trials may not predict later outcomes; the uncertain timing, cost, and outcome of preclinical and clinical development activities; risks related to the clinical trial process, including potential delays or failure to achieve effective trial design or positive results; the inability to obtain or maintain required regulatory approvals; limited market acceptance of the Company’s products, even if approved; the potential emergence of competing therapies that are safer, more effective, or more affordable; rapid technological change that may impact the relevance of the Company’s technologies; the Company’s dependence on key personnel and strategic partners; the inability to obtain adequate financing; risks related to the Company’s ability to protect its intellectual property; the possibility that the Company’s technologies, including its exosome-based platforms, may not achieve their intended therapeutic impact; the inability to produce or scale exosome-based products for clinical use; limited adoption in regenerative medicine or cell therapy applications; lack of growing clinical demand in targeted indications such as spinal cord injury, optic nerve repair, or other therapeutic areas; failure to meet planned development milestones or achieve commercial breakthroughs; the Company’s inability to have long-term protection of its intellectual property and/or manufacturing process; the Company’s exosomes will be not be regenerative; the Company will be unable to launch first-in-human clinical trials; the Company and Exo-Top Inc. will be unable to advance into clinical and/or commercial phases, launch commercial-scale production and/or business-to-business exosome supply, achieve scalability and/or advance their manufacturing methods; the NurExone platform technology not offering novel solutions to drug companies interested in minimally invasive targeted drug delivery for other indications; and the risks discussed under the heading “Risk Factors” on pages 44 to 51 of the Company’s Annual Information Form dated August 27, 2024, a copy of which is available under the Company’s SEDAR+ profile at www.sedarplus.ca. These factors should be considered carefully, and readers should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, the Company cannot assure readers that actual results will be consistent with these forward-looking statements. These forward-looking statements are made as of the date of this press release, and the Company assumes no obligation to update or revise them to reflect new events or circumstances, except as required by law.

Neither TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.

ⁱ Spinal cord injury, Glaucoma

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.